Come as You Are: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
Line 46:
⚡ '''6 – Arousal: Lubrication Is Not Causation.''' In 2010, a meta‑analysis led by Meredith Chivers pooled 132 laboratory studies published from 1969–2007—2,505 women and 1,918 men—to compare self‑reported arousal with genital measures. Agreement was much lower for women (about r=.26) than for men (about r=.66), showing that physiological response often diverges from felt desire or pleasure. Earlier experiments using vaginal photoplethysmography had already shown that many women’s genitals respond broadly to sexual cues while subjective interest stays specific; the meta‑analysis quantified the gap. That’s the engine behind the chapter’s mantra: lubrication is evidence of sexual relevance, not proof of wanting or liking. The text translates this into safety skills—ask, pause, and check in—because consent lives in words and choices, not in blood flow. It also normalizes “nothing happened” moments: the body can react automatically while the mind says no. For partners, the advice is concrete: don’t read wetness or erection as yes; look for enthusiastic participation and keep talking. For individuals, the move is self‑trust: notice sensations, then decide based on values and context. This resolves common misunderstandings about mismatched desire by distinguishing three signals—genital response, subjective arousal, and motivation to act. Core idea: arousal non‑concordance is normal; it makes consent and communication the ground truth. Mechanism: because genital response is a fast, relevance‑detection system, only context and cognition convert it into wanting—so “lubrication is not causation.”
❤️ '''7 – The ticker: confronting and preventing heart disease, the deadliest killer on the planet.''' In 1948, the Framingham Heart Study launched in Massachusetts and enrolled 5,209 men and women aged 30–62 to uncover what drives heart attacks and strokes; over decades it pinned risk on smoking, high blood pressure, high cholesterol, diabetes, and inactivity. That map set the stage for precision tools: the Multi‑Ethnic Study of Atherosclerosis (MESA) followed 6,814 adults starting in 2000–2002 and showed how a coronary artery calcium (CAC) scan quantifies plaque you can’t feel. In MESA and subsequent cohorts, a CAC score of 0 carried an annual event rate near 0.1%, the “power of zero” that can reclassify intermediate risk. When calcium is present—100, 300, or more—the 10‑year outlook shifts upward, and prevention needs to get aggressive. Blood work also gets sharper: apolipoprotein B (apoB) counts the number of atherogenic particles and often outperforms LDL‑C for predicting events. Put the pieces together and you get a practical stack: track apoB, scan when risk is uncertain, manage blood pressure, and build cardiorespiratory fitness that raises the ceiling on daily life. Statins, ezetimibe, PCSK9 inhibitors, and lifestyle changes aren’t rival camps—they’re instruments you layer to keep plaque burden low. Exercise is a drug here: higher VO₂max, stronger legs, and better glucose control make every artery more forgiving. The clock starts early, so the earlier the slope bends, the better the lifetime picture. Core idea: atherosclerosis is a decades‑long exposure problem—lower apoB particle burden and quantify plaque to change the odds you face later. Mechanism: use objective risk markers (apoB, CAC, blood pressure, fitness) to drive compounding behaviors and therapies before symptoms appear.
=== IV – Ecstasy For Everybody ===
🦠 '''8 – The runaway cell: new ways to address the killer that is cancer.''' In 2011, the National Lung Screening Trial randomized more than 53,000 high‑risk smokers to three annual low‑dose CT scans versus chest X‑rays and cut lung‑cancer mortality by roughly 20%, with about three fewer deaths per 1,000 people screened over ~7 years and a 6.7% drop in all‑cause mortality. Not all screens help equally: the U.S. PLCO trial enrolled ~155,000 people from 1993 to 2001 and, amid heavy PSA “contamination” in the control arm, showed no prostate‑cancer mortality benefit; meanwhile, the ERSPC trial reported a 20–21% prostate‑cancer mortality reduction with routine PSA testing at the cost of overdiagnosis. Colorectal screening offers multiple lanes: colonoscopy quality is tracked with adenoma detection rate benchmarks, while a 2014 NEJM study validated a multitarget stool‑DNA test that combines a hemoglobin immunoassay with assays for KRAS mutations and methylation of NDRG4 and BMP3. Guidelines have shifted screening earlier—into the mid‑40s—because incidence patterns changed, and flexible pathways (FIT, stool DNA, sigmoidoscopy, colonoscopy) let people match preference to risk. The thread through all of this is calibrated screening: hit the cancers where mortality moves and avoid tests that mainly uncover harmless disease. Layer in exposure control—don’t smoke, manage weight and insulin resistance, limit alcohol—and the baseline risk drops before any scan. Treatment is still improving, but the biggest wins come from catching lethal cancers sooner and avoiding the ones that never needed treatment. Core idea: make cancer a probability game you can influence—choose screenings with proven mortality benefit and reduce exposures that feed tumor biology. Mechanism: optimize expected value by pairing high‑yield tests (by age and risk) with long‑horizon habits so fewer dangerous cancers gain a foothold.
🧠 '''9 – Chasing memory: understanding Alzheimer's Disease and other neurodegenerative diseases.''' The Finnish FINGER trial randomized 1,260 adults aged 60–77 at elevated risk to two years of diet, exercise, cognitive training, and vascular risk management versus standard health advice and improved global cognition—proof that a multidomain program can move the needle. A 2011 randomized study in *PNAS* added a tissue‑level view: 120 older adults who walked briskly for a year increased anterior hippocampal volume by about 2% and boosted BDNF, shifting memory performance upward instead of down. Sleep connects the rest: rodent work from 2013 in *Science* showed that during sleep the interstitial space in the brain expands and glymphatic flow increases, enhancing clearance of metabolic waste including amyloid‑β. Vascular health, insulin sensitivity, mood stability, and fitness all show up as levers that either protect synapses or accelerate decline. High‑intensity intervals and heavy carries help the brain as much as the body by strengthening glucose handling, lowering inflammation, and preserving white matter “wiring.” Cognitive reserve is trained the same way muscles are trained: frequently, specifically, and with enough challenge to adapt. When labs and imaging are ambiguous, daily function—balance, recall, attention under fatigue—becomes the dashboard. Core idea: neurodegeneration is not one switch but a bundle of risks that can be pushed down together through movement, sleep, metabolic control, and targeted skill work. Mechanism: build brain resilience by compounding small, repeated stimuli (aerobic work, strength, sleep regularity, skill practice) that improve synaptic plasticity and reduce the toxic milieu that erodes memory.
== Background & reception ==
| |||